Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Description

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

Conditions

Hepatitis B, Cirrhosis, Liver, Chronic Liver Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.

Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.

Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis

Condition
Hepatitis B
Intervention / Treatment

-

Contacts and Locations

Baltimore

Mercy Medical Center, Baltimore, Maryland, United States, 21202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine.
  • * Those who had previous exposure to hepatitis B.
  • * Post liver transplant patients.
  • * Less than 18 years old.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Mercy Medical Center,

Paul Thuluvath, MD, PRINCIPAL_INVESTIGATOR, Mercy Medical Center

Study Record Dates

2028-12-01